NB-PP_1170x120

Eli Lilly

Eli Lilly to offer insulin discounts via Blink Health

Eli Lilly to offer insulin discounts via Blink Health

INDIANAPOLIS — Eli Lilly and Co. has partnered with Express Scripts to enable diabetes patients to access discounts for Lilly insulin products through digital drug search and pricing service Blink Health. Lilly said Tuesday that the discounted prices for its insulin are slated to become available on Jan. 1 through Blink Health mobile and web

Jardiance approved to cut cardiovascular death risk

Jardiance approved to cut cardiovascular death risk

RIDGEFIELD, Conn., and INDIANAPOLIS — Jardiance tablets, marketed by Boehringer Ingelheim and Eli Lilly and Co., have been approved by the Food and Drug Administration to cut the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. BI and Lilly said the FDA clearance makes Jardiance (empagliflozin) the first type

Eli Lilly promotes pair of finance executives

Eli Lilly promotes pair of finance executives

INDIANAPOLIS — Eli Lilly and Co. has appointed Joshua Smiley as senior vice president of finance and treasurer. Lilly said Wednesday that Smiley, currently senior vice president of finance, controller and chief financial officer for Lilly Research Laboratories, assumes his new post on Oct. 1. He replaces Thomas Grein, who will retire in September after a

Lilly, BI cleared to market Basaglar long-acting insulin

Lilly, BI cleared to market Basaglar long-acting insulin

INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. have received approval for Basaglar long-acting insulin (insulin glargine injection, 100 units/ml) in the United States. The companies said Basaglar has an identical amino acid sequence to Lantus, another U-100 insulin glargine, and is delivered via the prefilled Basaglar KwikPen. Basaglar

FDA approves Boehringer Ingelheim, Eli Lilly’s Synjardy

FDA approves Boehringer Ingelheim, Eli Lilly’s Synjardy

RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. have received approval from the Food and Drug Administration for Synjardy tablets, a medication for type 2 diabetes. The companies said Thursday that Synjardy (empagliflozin and metformin hydrochloride) marks their third product containing empagliflozin to be approved by the FDA, following

Eli Lilly ships Humalog U-200 KwikPen

Eli Lilly ships Humalog U-200 KwikPen

INDIANAPOLIS — Eli Lilly & Co. has rolled out the Humalog 200 units/ml KwikPen to U.S. pharmacies, calling the medication the nation’s first and only concentrated mealtime insulin analog. Lilly said Tuesday that the Humalog U-200 KwikPen (insulin lispro 200 units/ml) prefilled pen contains a concentrated formulation of the company’s rapid-acting insulin Humalog (insulin lispro 100

Lilly marks a first with Humalog U-200 KwikPen

Lilly marks a first with Humalog U-200 KwikPen

INDIANAPOLIS — Eli Lilly and Co. has been cleared by the Food and Drug Administration to market the Humalog 200 units/ml KwikPen, which the company called the first concentrated mealtime insulin analog approved in the United States. Lilly said Wednesday that the Humalog 200 units/ml KwikPen (insulin lispro 200 units/ml, U-200) is a prefilled pen